Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
318 Results for "
microenvironment
" in MedChemExpress (MCE) Product Catalog:
Products (318)
318 Results for "microenvironment" in MCE Product Catalog:
1
1 Cited Publications
Target:
Forschungsgebiete:
BTYNB is a structure-specific nucleic acid binder and IGF2BP1 inhibitor (with an IC50 of 5 μM against hBTYNB). BTYNB disrupts the IGF2BP1-RNA interaction and blocks its binding to oncogenic mRNAs such as c-Myc, MDM2, PD-L1. BTYNB completely blocks the INHBA-Smad2/3 pathway, disrupts the MYCN/IGF2BP1 loop, and thereby induces apoptosis and cell cycle arrest, effectively inhibiting the proliferation and survival of cancer cells. In addition, BTYNB acts as an immune activator and tumor microenvironment modulator, enhances T cell-mediated tumor killing, and produces significant synergistic effects with inhibitors of PD-1, BRD and BIRC5. BTYNB can be used in relevant research on various malignant tumors including ovarian cancer, neuroblastoma, leukemia and melanoma .
1
1 Cited Publications
Art. -Nr.: HY-P1181A
Forschungsgebiete:
Cardiovascular Disease Infection Inflammation/Immunology Cancer
1
1 Cited Publications
Art. -Nr.: HY-N0909
CAS. Nr.: 80418-25-3
Synonyms: 20(S)-Notoginsenoside R2; Ginsenoside Ng-R2
1
1 Cited Publications
Art. -Nr.: HY-P990297
Forschungsgebiete:
1
1 Cited Publications
Art. -Nr.: HY-N0819
CAS. Nr.: 89412-79-3
Synonyms: FLX475
Target:
Forschungsgebiete:
Tivumecirnon (FLX475) is an orally active, selective CCR4 antagonist. Tivumecirnon blocks the binding of CCR4 to its ligands, CCL17 and CCL22, thereby reducing Treg infiltration into the tumor microenvironment. Tivumecirnon has antitumor activity .
Art. -Nr.: HY-P991097
Synonyms: PM-8002; BNT-327
Target:
Forschungsgebiete:
Art. -Nr.: HY-P99643
CAS. Nr.: 2390147-17-6
Synonyms: UCB6114
Target:
Forschungsgebiete:
Art. -Nr.: HY-160421
CAS. Nr.: 2000236-36-0
Target:
Forschungsgebiete:
TREM2-IN-1 (OPA) is a TREM2 inhibitor derived from oxaliplatin and artesunate. TREM2-IN-1 can relieves immunosuppressive tumor microenvironment and enhancing chemical anticancer efficiency. TREM2-IN-1 deters the tumor growth in mice models bearing MC38 colorectal tumor by reducing the number of CD206 + and CX3CR1 + immunosuppressive macrophages. TREM2-IN-1 also promotes the expansion and infiltration of immunostimulatory dendritic, cytotoxic T and natural killer cells .
ODM-203 is an orally active and selective FGFR/VEGFR inhibitor with IC50 values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and VEGFR3/2/1/4, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment .
Target:
Art. -Nr.: HY-P99046
CAS. Nr.: 1622140-49-1
Synonyms: CP-870893; RG-7876
Target:
Forschungsgebiete:
Art. -Nr.: HY-P990042
CAS. Nr.: 2226344-78-9
Synonyms: ONC-392; BNT 316
Target:
Forschungsgebiete:
Art. -Nr.: HY-P4116
CAS. Nr.: 2293160-09-3
Synonyms: pHLIP
Target:
Forschungsgebiete:
Target:
Forschungsgebiete:
ALV2 is a potent and selective Helios molecular glue degrader. ALV2 binds CRBN, with an IC50 of 0.57 μM. Helios is the zinc-finger transcription factor that can maintain a stable Treg cell phenotype in the inflammatory tumor microenvironment .
Art. -Nr.: HY-P99118
CAS. Nr.: 2231029-82-4
Synonyms: HLX 10
Target:
Forschungsgebiete:
Synonyms: TT 00420
Target:
Forschungsgebiete:
Tinengotinib (TT00420) is an orally active, spectrally selective small molecule kinase inhibitor targeting Aurora A/B (IC50=1.2-3.3 nM), FGFR1/2/3 (IC50=1.5-3.5 nM), VEGFRs, JAK1/2 and CSF1R. Tinengotinib blocks Aurora kinase-mediated cell cycle progression (inducing G2/M arrest), inhibits FGFR/JNK-JUN signaling pathway and activates MEK/ERK-dependent apoptotic pathway. Tinengotinib has the activity of anti-tumor proliferation, inducing apoptosis, inhibiting angiogenesis and regulating tumor microenvironment. Tinengotinib can be used in the study of triple-negative breast cancer (TNBC), gallbladder cancer and tumor immune microenvironment .
Art. -Nr.: HY-134958
CAS. Nr.: 31852-29-6
Synonyms: Poly(I:C) potassium
Target:
Forschungsgebiete:
Polyinosinic-polycytidylic acid potassium (Poly(I:C) potassium) is a synthetic analog of double-stranded RNA and an agonist of toll-like receptor 3 (TLR3) and retinoic acid inducible gene I (RIG-I)-like receptors (RIG-I and MDA5). Polyinosinic-polycytidylic acid sodium can be used as a vaccine adjuvant to enhance innate and adaptive immune responses, and to alter the tumor microenvironment. Polyinosinic-polycytidylic acid potassium can directly trigger cancer cells to undergoApoptosis .
PROTAC PARP1 degrader-1 is a PARP1 PROTAC degrader with a DC50 value of 252.5 nM. PROTAC PARP1 degrader-1, combined with Daunorubicin (HY-13062A), induces the accumulation of cytoplasmic DNA fragments, activates the cGAS/STING innate immune pathway, and remodels the tumor microenvironment. PROTAC PARP1 degrader-1 can be used in research related to breast cancer .
Art. -Nr.: HY-P990651
Target:
Forschungsgebiete:
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
